CN110996918A - Hsp90抑制剂口服配制品和相关方法 - Google Patents

Hsp90抑制剂口服配制品和相关方法 Download PDF

Info

Publication number
CN110996918A
CN110996918A CN201880040143.1A CN201880040143A CN110996918A CN 110996918 A CN110996918 A CN 110996918A CN 201880040143 A CN201880040143 A CN 201880040143A CN 110996918 A CN110996918 A CN 110996918A
Authority
CN
China
Prior art keywords
optionally
compound
capsule
tablet
hsp90
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880040143.1A
Other languages
English (en)
Chinese (zh)
Inventor
J.阿梅迪奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samus Treatment Co Ltd
Original Assignee
Samus Treatment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samus Treatment Co Ltd filed Critical Samus Treatment Co Ltd
Publication of CN110996918A publication Critical patent/CN110996918A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880040143.1A 2017-04-24 2018-04-24 Hsp90抑制剂口服配制品和相关方法 Pending CN110996918A (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201762489434P 2017-04-24 2017-04-24
US201762489438P 2017-04-24 2017-04-24
US62/489,438 2017-04-24
US62/489,434 2017-04-24
US201762532985P 2017-07-14 2017-07-14
US201762532987P 2017-07-14 2017-07-14
US62/532,987 2017-07-14
US62/532,985 2017-07-14
US201762588893P 2017-11-20 2017-11-20
US201762588897P 2017-11-20 2017-11-20
US62/588,893 2017-11-20
US62/588,897 2017-11-20
US201862627229P 2018-02-07 2018-02-07
US201862627237P 2018-02-07 2018-02-07
US62/627,237 2018-02-07
US62/627,229 2018-02-07
PCT/US2018/029157 WO2018200534A1 (en) 2017-04-24 2018-04-24 Hsp90 inhibitor oral formulations and related methods

Publications (1)

Publication Number Publication Date
CN110996918A true CN110996918A (zh) 2020-04-10

Family

ID=63918615

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040143.1A Pending CN110996918A (zh) 2017-04-24 2018-04-24 Hsp90抑制剂口服配制品和相关方法

Country Status (11)

Country Link
US (1) US20200069592A1 (https=)
EP (1) EP3615008A4 (https=)
JP (1) JP2020517732A (https=)
KR (1) KR20190138871A (https=)
CN (1) CN110996918A (https=)
AU (2) AU2018257901A1 (https=)
CA (1) CA3061185A1 (https=)
IL (1) IL296355A (https=)
SG (2) SG11201909825VA (https=)
TW (1) TWI782982B (https=)
WO (1) WO2018200534A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
CN114259564A (zh) * 2021-11-30 2022-04-01 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
US12042491B1 (en) * 2022-12-30 2024-07-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of quinolines
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
US20260090985A1 (en) * 2024-10-02 2026-04-02 Aspire Biopharma Holdings, Inc. Oral mucosal formulations of aspirin
CN119360948B (zh) * 2024-10-10 2025-12-02 中国人民解放军军事科学院军事医学研究院 一种基于黄芪和camk2b的计算机辅助方法、系统或设备

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983191A (zh) * 2008-02-01 2011-03-02 武田药品工业株式会社 作为hsp90抑制剂的肟衍生物
WO2012131468A1 (en) * 2011-03-25 2012-10-04 Debiopharm Sa Crystalline forms of fused amino pyridines as hsp90 inhibitors
US20120277257A1 (en) * 2009-11-13 2012-11-01 Myrexis, Inc. Methods of Treating Diseases, Pharmaceutical Compositions, and Pharmaceutical Dosage Forms
CN104173283A (zh) * 2014-08-27 2014-12-03 广州暨南生物医药研究开发基地有限公司 一种以苯甲酰胺为基本骨架的Hsp90抑制剂的纳米混悬剂及其制备方法
CN104812898A (zh) * 2012-05-25 2015-07-29 博格有限责任公司 通过调节热休克蛋白质(HSP)90-β治疗代谢综合征的方法
US20150253330A1 (en) * 2012-05-16 2015-09-10 Synta Pharmaceuticals Corp. Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
JP5063815B2 (ja) * 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
JP5941407B2 (ja) * 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
EP2498759B1 (en) * 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
EP2972394A4 (en) * 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
PE20160605A1 (es) * 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk
WO2015191610A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
TW201609108A (zh) * 2014-07-25 2016-03-16 諾華公司 醫藥劑型
KR20170033358A (ko) * 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983191A (zh) * 2008-02-01 2011-03-02 武田药品工业株式会社 作为hsp90抑制剂的肟衍生物
US20120277257A1 (en) * 2009-11-13 2012-11-01 Myrexis, Inc. Methods of Treating Diseases, Pharmaceutical Compositions, and Pharmaceutical Dosage Forms
WO2012131468A1 (en) * 2011-03-25 2012-10-04 Debiopharm Sa Crystalline forms of fused amino pyridines as hsp90 inhibitors
US20150253330A1 (en) * 2012-05-16 2015-09-10 Synta Pharmaceuticals Corp. Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
CN104812898A (zh) * 2012-05-25 2015-07-29 博格有限责任公司 通过调节热休克蛋白质(HSP)90-β治疗代谢综合征的方法
CN104173283A (zh) * 2014-08-27 2014-12-03 广州暨南生物医药研究开发基地有限公司 一种以苯甲酰胺为基本骨架的Hsp90抑制剂的纳米混悬剂及其制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
CN114259564A (zh) * 2021-11-30 2022-04-01 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN114259564B (zh) * 2021-11-30 2023-03-14 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用

Also Published As

Publication number Publication date
TWI782982B (zh) 2022-11-11
EP3615008A1 (en) 2020-03-04
KR20190138871A (ko) 2019-12-16
SG10201913562VA (en) 2020-03-30
EP3615008A4 (en) 2021-05-05
IL296355A (en) 2022-11-01
TW201904564A (zh) 2019-02-01
AU2018257901A1 (en) 2019-11-14
CA3061185A1 (en) 2018-11-01
JP2020517732A (ja) 2020-06-18
AU2022256110A1 (en) 2022-11-17
US20200069592A1 (en) 2020-03-05
WO2018200534A1 (en) 2018-11-01
SG11201909825VA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CN110996918A (zh) Hsp90抑制剂口服配制品和相关方法
JP7627302B2 (ja) パルボシクリブの固形剤形
ES2741800T3 (es) Formulación de acetato de abiraterona
JP5537943B2 (ja) 速崩壊性固形製剤
TWI540128B (zh) 醫藥組合物
CN105073099B (zh) 有机化合物的制剂
WO2012172461A1 (en) Pharmaceutical compositions of febuxostat
US8987285B2 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
US20220160698A1 (en) Pharmaceutical oral liquid solution of ivacaftor
HK40027692A (en) Hsp90 inhibitor oral formulations and related methods
US20090269409A1 (en) Pharmaceutical compositions comprising eszopiclone
KR20070118247A (ko) 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
EP3334419A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2007029093A2 (en) Pharmaceutical dosage forms of oxcarbazepine
US20250325517A1 (en) Oral dosage forms of elraglusib
EP4623916A1 (en) Oral solid formulation
WO2026019402A1 (en) A pharmaceutical composition comprising nanosuspension of canagliflozin
JP2025542194A (ja) （ｒ）－１－（１－アクリロイルピペリジン－３－イル）－４－アミノ－３－（４－フェノキシフェニル）－１ｈ－イミダゾ［４，５－ｃ］ピリジン－２（３ｈ）－オンの製剤
EP4648753A1 (en) Compositions for the treatment of cftr-mediated diseases
HK40063384A (en) Solid dosage forms of palbociclib
HK40119846A (zh) Elraglusib的口服剂型
SA112330839B1 (ar) تركيب صيدلي وطريقة لتحضيره

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027692

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20200410

RJ01 Rejection of invention patent application after publication